Table of contents:
Triple antiviral therapy showed good effect on COVID-19 - study
In a small study, a combination of antiviral drugs helped COVID-19 patients. They recovered faster, and their SARS-CoV-2 tests turned negative much earlier.
Photo: CC0 Public Domain
Triple antiviral therapy has shown promising results in the treatment of COVID-19. Scientists tested the effect of a combination of antiviral agents: interferon beta-1b, lopinavir / ritonavir and ribavirin. The report was published in The Lancet.
The effect of triple antiviral therapy has been tested in a phase II clinical trial, i.e. in a small number of patients. Scientists emphasize that the effectiveness of such treatment can be finally declared after a large study (phase III).
The study involved 127 people, they were randomly assigned to two groups. Against the background of standard COVID-19 treatment, the participants in the first group received triple therapy (interferon beta-1b, lopinavir / ritonavir and ribavirin), the second - treatment with lopinavir / ritonavir alone for 14 days.
Patients who received triple therapy tested positive for COVID-19 for an average of 7 days. They stopped shedding the virus significantly earlier than those who received lopinavir / ritonavir: in patients in this group, the tests were positive on average within 12 days.
In this study, the beneficial effect of triple therapy was expressed in patients who started treatment within the first seven days of illness. Those who started receiving the drugs later did not show significant improvement.
Patients who started receiving triple therapy on time had faster symptom relief (4 versus 8 days), and they were discharged from the hospital earlier (9 versus 14.5 days).
“Our research shows that early use of a triple combination of antiviral drugs can rapidly reduce the number of viruses in patients, relieve symptoms and reduce the risk to healthcare providers by reducing the duration and amount of virus shedding. In addition, the treatment was well tolerated by the patients,”said Kwok-Yung Yuen, a professor at the University of Hong Kong and co-author of the study.